围绕数据这一关键基础，徐仲煌认为，高质量数据并不仅仅是技术层面的积累，更是医疗流程设计的结果。他介绍，北京美中爱瑞肿瘤医院在建设过程 中，从流程源头入手，尽量减少信息割裂，让临床、影像、病理以及患者服务相关数据能够在实际业务中被持续理解和调用，为智能化协作提供基础支撑。 得益于字节跳动技术体系在数字化和智能化方面的整体布局，医院在探索AI应用时，能够更快地将技术嵌入真实业务场景，形成闭环优化。 "从更长远的角度看，人工智能对医疗行业的影响，不仅体现在效率提升上，更体现在重塑医疗工作的协作方式上。"徐仲煌说，随着AI在医疗场景中的 深入应用，医生的核心价值将更加集中在高质量判断、人际沟通和复杂决策上。能够理解AI、善于与智能系统协作，并在此基础上持续提升专业能力的医 务工作者，将在未来的医疗体系中更具竞争力。 徐仲煌结合北京美中爱瑞肿瘤医院的实践介绍，作为字节跳动体系的医院，美中爱瑞有着良好的数据基因。在推进智能化建设过程中，并未将AI简单 视为某一个系统或功能模块，而是尝试让AI更早、更深入地参与到诊疗流程之中。例如，在门诊和多学科诊疗（MDT）前，通过智能化方式对患者既往病 历、影像检查、病理报告及主诉信息 ...

格隆汇12月23日丨希玛医疗(03309.HK)发布公告，2025年12月23日耗资40.75万港元回购24万股，回购 价格每股1.69-1.7港元。 ...

希玛医疗(03309)发布公告，于2025年12月23日，该公司斥资40.75万港元回购24万股股份，每股回购价 格为1.69-1.7港元。 ...

每经头条（nbdtoutiao）——地产"优等生"受困20亿元到期债务，首次债务展期仍在博弈，明年还有超 百亿元公开债到期 2025年1至6月份，华邦健康的营业收入构成为：农药占比56.82%，医药行业占比27.33%，旅游业占比 8.29%，其他占比4.34%，医疗服务行业占比3.21%。 （记者 王晓波） 每经AI快讯，华邦健康（SZ 002004，收盘价：4.83元）12月23日晚间发布公告称，公司第九届第四次 董事会会议于2025年12月23日通过通讯表决的方式召开。会议审议了《关于修订 <独立董事工作制度> 的议案》等文件。 截至发稿，华邦健康市值为96亿元。 ...

证券之星消息，12月23日医疗服务板块较上一交易日下跌0.75%，数字人领跌。当日上证指数报收于 3919.98，上涨0.07%。深证成指报收于13368.99，上涨0.27%。医疗服务板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗服务板块主力资金净流出7.47亿元，游资资金净流入1.03亿元，散户资金 净流入6.44亿元。医疗服务板块个股资金流向见下表： ...

Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.14% this week, ranking 22nd among the 31 primary industries in the Shenwan index [2] - The medical services sub-sector showed a positive performance with a 0.55% increase, while the chemical pharmaceuticals sub-sector declined by 1.74% [2] Industry Performance - The medical services sector's PE (ttm) is 31.74X, and PB (lf) is 3.20X, with a slight increase in both metrics compared to the previous week [5] - Notable performers in the medical services sector include Meinian Health (+24.1%) and Baihua Medicine (+8.8%), while underperformers include Nanhua Biology (-6.5%) and Meidisi (-5.2%) [4] Legislative Impact - The U.S. 2026 National Defense Authorization Act (NDAA) has passed, incorporating the revised Biotech Safety Act, which limits federal contracts with certain biotechnology providers, potentially easing immediate impacts on the domestic biopharmaceutical industry [6][7] - The revised NDAA does not directly name specific companies, which may reduce the immediate shock to the industry [7] Investment Recommendations - The report maintains a "buy" rating for the medical services sector, highlighting high-growth opportunities in ADC CDMO and peptide CDMO companies like WuXi AppTec and Haoyuan Pharmaceutical [8] - It also suggests focusing on companies with expected improvements in profitability, such as Aier Eye Hospital and Dian Diagnostics [8]

Core Insights - 吉祥航空 and Shanghai Jiao Tong University School of Medicine's Ruijin Hospital have announced a strategic partnership aimed at enhancing airborne medical emergency capabilities, focusing on aviation medicine, employee health services, and passenger care [1][2] Group 1: Strategic Collaboration - The collaboration will establish a "remote medical emergency guidance platform" on 吉祥航空's Boeing 787 aircraft, allowing crew members to connect with Ruijin Hospital's support team for real-time medical consultation during flights [2] - This platform aims to improve the timeliness and effectiveness of in-flight medical responses, ensuring better coordination with ground medical resources for post-landing care [2] Group 2: Health Services Integration - The partnership will integrate professional medical resources into the aviation service ecosystem, enhancing health and safety levels for civil aviation practitioners [3] - Ruijin Hospital will provide comprehensive health services for 吉祥航空 employees, including pre-employment physicals and customized health management [3] - The collaboration will also explore tailored health care services for 吉祥航空's members and business travelers, creating a new "aviation + health" experience throughout the travel journey [3]

Core Insights - The establishment of the Jiangsu Province Refractory Relapsed Leukemia Diagnosis and Treatment Collaboration Group aims to address the challenges faced by patients with difficult-to-treat leukemia, particularly in terms of access to effective medical resources and treatment options [2][3][7] - The collaboration involves 186 medical institutions, including top-tier hospitals and various healthcare facilities, to create a comprehensive platform for precise diagnosis, management, and the introduction of new drugs and technologies [2][3][6] Group 1: Medical Resource Distribution - Only 30% of local hospitals in China can provide standardized treatment for refractory relapsed leukemia, forcing approximately 80% of patients to seek care outside their regions [1] - The collaboration group is designed to improve the distribution of medical resources and enhance the treatment capabilities for severe and complex cases of leukemia [3][6] Group 2: Technological Innovation - The blood department at Southeast University Affiliated Zhongda Hospital has developed a key gene panel detection technology for acute leukemia, which has significant clinical value and has won awards for its innovation [4][5] - The team has created personalized treatment plans, particularly excelling in the integration of traditional Chinese and Western medicine for acute myeloid leukemia [4][5] Group 3: Collaborative Platforms - The collaboration group will establish eight platforms focusing on various aspects such as precise diagnosis, traditional and modern treatment integration, technological innovation, telemedicine, and training for medical personnel [6][7] - The initiative aims to leverage big data and artificial intelligence to support individualized treatment and plans to achieve comprehensive coverage of leukemia treatment services across the province within three years [7]

佰泽医疗(02609)盘中跌超6%，当前股价较9月高点已跌超50%。截至发稿，跌5.24%，报4.34港元，成 交额2529.52万港元。 消息面上，佰泽医疗基石投资者禁售期即将届满。据公司此前发布公告显示，其基石投资者Harvest Oriental SP须遵守禁售承诺最后日期为2025年12月23日，解禁股数约3531.78万股。今年上半年，佰泽医 疗实现收入5.75亿元(人民币，下同)，同比增加约0.7%；经调整净利润940万元，同比增长约72.8%。 ...

Group 1 - The core theme of the 20th China Insurance Innovation Forum is "Co-creation and Symbiosis," focusing on how medical services can empower the insurance industry [1][12] - Bai Hua, Chairman and CEO of Yuanhe Medical, emphasized that traditional insurance companies struggle to participate in the medical service process, leading to limited cost control effectiveness [1][12] - Yuanhe Medical holds a 47.8% market share in the non-public medical market in the UK, with 57 hospitals, including 37 general hospitals and 20 specialized hospitals [4][15] Group 2 - The healthcare system in Europe and the US differs significantly from China's, with quality clinical resources held by experts rather than institutions [4][15] - Yuanhe Medical was founded by over 3,000 medical experts who recognized the limitations of medical capabilities and established a managed care model to intervene early in diseases [5][16] - The UK government has transferred public healthcare services to professional institutions, with Yuanhe Medical being the first to manage the public healthcare system [6][17] Group 3 - The essence of insurance is as a payer, and controlling costs is a critical issue; however, the relationship between healthcare providers and insurers often leads to a confrontational dynamic [6][17] - The transition to a 2.0 phase involves controlling disease occurrence rather than relying on patient illness for profit, aligning the values of medical service providers with those of insurance companies [6][18] - Centene Corporation's acquisition of Yuanhe Medical allowed it to enter the European market, focusing on health insurance, which has become a primary direction for the insurance industry in Europe and the US [8][19] Group 4 - In 2024, Yuanhe Medical underwent significant changes with its major shareholder becoming Pure Health, a sovereign fund from the UAE, which also controls a large US healthcare group [9][20] - Pure Health is investing heavily in drug research and development, becoming a significant player in the global biopharmaceutical investment landscape [20][21] - The UAE has established the world's first comprehensive "Longevity Health Management" medical guidelines, reflecting a shift towards preventive health management [21][22] Group 5 - The core of high-end medical insurance lies in cost control, which is challenging for insurance companies that cannot directly engage in medical services [11][22] - Many insurance companies invest heavily in value-added health insurance services, but the effectiveness in improving client health outcomes and reducing claims remains questionable [11][22] - There is a need for deeper collaboration between insurance companies and medical service providers to enhance customer service experiences and better control costs [11][22]